Human hepsin protein
≥ 5.0 mg/ml
< 1.0 EU/mg as determined by the LAL method
≥95% monomer by analytical SEC
>95% by SDS Page
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
Next Day 2-8°C
Applications and Recommended Usage?
Quality Tested by Leinco
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.
Clone 3H10.1.2 is able to recognize full-length native Hepsin expressed on the cell surface in addition to the recombinant soluble form. Clones 3H1.1.1 and 1F2.1.1 bind to the same epitope as clone 3H10.1.2 and inhibit it (and each other) from binding Hepsin. Clone 3H10.1.2 and clone 2D5.1.9 bind separate epitopes and do not inhibit each other from binding Hepsin.
Hepsin is expressed on the surface of epithelial cells including the liver, kidney, prostate, and thyroid in human tissues.
Hepsin is a type II transmembrane serine protease (TTSP) expressed on the surface of epithelial cells including the liver, kidney, prostate, and thyroid in human tissues. The physiological function of hepsin is unclear, although, In vitro studies have shown that hepsin activates blood clotting factors VII, XII, and IX, pro-urokinase (pro-uPA), and pro-hepatocyte growth factor (pro-HGF). The over-expression of hepsin has been implicated in several types of cancer, especially ovarian and prostate, which makes it an attractive diagnostic marker for cancers. Most notably, hepsin has been identified as one of the most highly induced genes in prostate cancer, and this over-expression is correlated with the cancer progression and metastasis. Furthermore anti-hepsin antibodies have been shown to inhibit the invasion of human prostate cancer cells.1
NCBI Gene Bank ID
References & Citations
1. Wu,Q. and Parry, G. (2007) Front Biosci 12 5052-9
2. Kirchhofer, D. et al. (2006) J Biol Chem.281(41):30439-46.
Products are for research use only. Not for use in diagnostic or therapeutic procedures.